|
 |
BicalutamideThis page contains recent news articles, when available, and an overview of Bicalutamide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Bicalutamide (when available) Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. Mechanism Of Action: Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. News Articles on Bicalutamide Commercial Insight: Antihormonal Cancer Therapies - New Report Published - Jan 3, 2010 In 2008, Arimidex (anastrozole; AstraZeneca), Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca) were the three leading antihormonal ... OfficialWire (press release) Frequency of zoledronic acid to prevent further bone loss in osteoporotic ... - Dec 15, 2009 Patients were randomly assigned to receive either LHRHA (29) or bicalutamide (29). All received 4 mg ZA 3-monthly for 1 year. ... UroToday SUO 2009 - Antitumor activity of MDV3100 in a phase 1-2 trial in castration ... - Dec 9, 2009 MDV3100 is a second generation anti-androgen active in bicalutamide resistant tumors. MDV3100 inhibits nuclear translocation to a greater degree than ... UroToday SUO 2009 - ADT and cancer stem cells: Novel findings with clinical ... - Dec 9, 2009 Their work then used LNCaP-Bic and C4-2 cell lines that grow without androgen and are clonogenic under bicalutamide exposure. ... UroToday Prostate cancer treatment linked to greater risk of heart disease and diabetes - Dec 11, 2009 The drugs, taken in daily pill form, include flutamide (Euflex) and bicalutamide (Casodex). “Patients and physicians considering initiation of GnRH agonist ... Globe and Mail Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co ... - Oct 27, 2009 MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions - MDV3100 blocks testosterone binding to the ... Reuters Hormone Therapy For Prostate Cancer - Nov 9, 2009 Anti-androgens - these drugs include flutamide and bicalutamide, as well as other drug names. These stop the hormone testosterone from reaching the cancer ... EmpowHer (blog) Astellas licenses Medivation's prostate cancer candidate - Oct 28, 2009 ...“to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgenâ€?, Medivation says. ... Pharma Times BREAKING NEWS: AstraZeneca sales boosted by swine flu vaccine - Oct 29, 2009 Turnover of the breast cancer drug Arimidex (anastrozole) were up 2% to $476 million, while generic competition to Casodex (bicalutamide) saw the drug fall ... Pharma Times Commercial Insight: Antihormonal Cancer Therapies - Stagnant sales indicative ... - Oct 30, 2009 In 2008, Arimidex (anastrozole; AstraZeneca), Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca) were the three leading antihormonal ... PRMinds (press release) FARMACI: FEDERFARMA, COME EVITARE DISCRIMINAZIONI TRA MALATI - Nov 13, 2009 I farmaci a base del principio attivo 'Bicalutamide' per la cura del carcinoma alla prostata, vengono distribuiti per la quasi totalita' in farmacia nella ... AGI - Agenzia Giornalistica Italia ì „ë¦½ì„ ì•” ì¹˜ë£Œì œ 시장 '확대ì?¼ë¡œ' - Nov 11, 2009 ...현재 시장ì?€ 호르몬 ì?˜ì¡´ ì „ë¦½ì„ ì•” 치료ì—? 주로 처방ë?˜ëŠ” '졸ë?¼ë?±ìŠ¤'(Zoladex, goserelin), '카소ë?±ìŠ¤'(Casodex, bicalutamide), 'ë£¨í”„ë¡ '(Lupron, euprolide), ... 디지틀보사 아스텔ë?¼ìŠ¤, ë©”ë””ë² ì?´ì…˜ ì „ë¦½ì„ ì•” ì‹ ì•½ ê¸°ìˆ ì œíœ´ - Oct 29, 2009 MDV3100ì?€ 새로운 경구용 í• ì•ˆë“œë¡œì 약물로 ì „ ìž„ìƒ?연구ì—?ì„œ 아스트ë?¼ì œë„¤ì¹´ì?˜ 카소ë?±ìŠ¤(Casodex: bicalutamide)보다 ë?” ê°•ë ¥í•œ 안드로ì 수용체 경로 차단작용ì?„ ... 메디포뉴스 High-dose bicalutamide after radiotherapy for locally advanced... - Nov 9, 2006 See WA et al. (2006) The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate ... Nature.com Adjuvant bicalutamide for early prostate cancer: an update - Mar 22, 2006 McLeod DG et al. (2006) Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97: 247–254 PubMed ... Nature.com Locally advanced prostate cancer treated with radiotherapy and … - Jan 25, 2005 Management Hormonal down-staging with bicalutamide 150 mg/day for 3 ... The patient received adjuvant bicalutamide 150 mg/day, initially for 6 months. ... Nature.com … May Reduce Breast Pain, Gynecomastia Associated With Bicalutamide - Apr 15, 2005 Bicalutamide is a potent, well-tolerated nonsteroidal antiandrogen being investigated as ... Of the 51 patients in the bicalutamide-only group, 35 developed ... Medscape Fake prostate drug recalled - Jun 2, 2007 The counterfeit prostate cancer drug contains only 75% of the active ingredient, Bicalutamide, so within weeks of taking it men could start suffering worse ... guardian.co.uk AstraZeneca gets 6-month exclusivity for Casodex from FDA - Sep 22, 2008 AstraZeneca Plc. it has been granted an additional six-month exclusivity from the US Food and Drug Administration to market Casodex (bicalutamide) for its ... Forbes … Data on Deforolimus and Bicalutamide in Androgen-Independent … - Oct 23, 2008 ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with ... International Business Times … Data On Deforolimus And Bicalutamide In Androgen-Independent … - Oct 24, 2008 ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with ... Medical News Today - Medical News Today (press release) Casodex (bicalutamide) 150mg, cost effective treatment for the … - Jan 18, 2005 New health economic data published today in the European Journal of Hospital Pharmacy outline the cost benefits of the non-steroidal anti-androgen ... Medical News Today - Medical News Today (press release) Supplement promoted prostate cancer - Jan 15, 2008 ...than testosterone and attempts to stop the cancer-cell growth with increasing concentrations of the anti-cancer drug bicalutamide proved to be futile. ... United Press International Bicalutamide Added to Radiotherapy Improves Prostate Cancer Survival - Sep 11, 2006 NEW YORK SEP 11, 2006 (Reuters Health) - Daily treatment with bicalutamide (Casodex) following radiotherapy appears to improve the survival of men with ... Cancerpage.com Prostate Cancer - Casodexо 150mg plus Radiotherapy Extends Life … - Nov 7, 2005 Bicalutamide 150mg is the only anti-androgen for which this has been shown.1 ... Results also confirm that treatment with bicalutamide 150mg significantly ... Medical News Today - Medical News Today (press release) Prostate Cancer Treatment (PDQ®) - Stage I Prostate Cancer - Jul 2, 2008 Bicalutamide has not been shown to improve OS in patients with localized or locally advanced prostate cancer. The Early Prostate Cancer program is a large, ... WebMD Bentley Pharma's bicalutamide gets Spanish OK.(Bentley … - Mar 12, 2007 New Hampshire, USA-based speciality drugmaker Bentley Pharmaceuticals says that its anticancer product bicalutamide, the generic equivalent to AstraZeneca's ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Adjuvant Treatment with Bicalutamide in the North American Cohort of... - Jul 31, 2006 BERKELEY, CA (UroToday.com) - The Early Prostate Cancer Trial (EPC) consisted of three international groups of patients treated with either placebo or ... UroToday International Journal Case study: management of advanced prostate cancer with soft tissue … - May 20, 2005 Among the nonsteroidal antiandrogens, bicalutamide 150 mg offers an attractive ... 3 Although this patient is responding well to bicalutamide 150 mg, ... Nature.com Adjuvant Treatment With Bicalutamide In The N American Cohort Of The ... - Aug 2, 2006 The Early Prostate Cancer Trial (EPC) consisted of three international groups of patients treated with either placebo or bicalutamide in addition to ... Medical News Today - Medical News Today (press release) Learn about Bicalutamide from Consumer Reports Health. - Jan 3, 2008 Bicalutamide is used with another medication (luteinizing hormone-releasing hormone [LHRH]; such as leuprolide or goserelin) to treat metastatic prostate ... consumerreports.org Bicalutamide helps prostate cancer survival - Sep 26, 2006 Bicalutamide (Casodex) is an antiandrogen or hormonal therapy. Daily treatment with bicalutamide is shown to cut the risk of progression of prostate cancer ... TopCancerNews.com Bentley Pharmaceuticals (BNT) Receives Spanish Approval for Generic … - Mar 7, 2007 Bicalutamide is the generic equivalent to AstraZeneca Pharmaceuticals' (NYSE: AZN) ... Bicalutamide is prescribed as a treatment to prevent the growth of ... StreetInsider.com - StreetInsider.com (subscription) Pharmac to fund prostate treatments - Oct 1, 2008 From today finasteride (Fintral) will be funded for BPH, and from November 1 bicalutamide (Bicalox) will be funded for advanced prostate cancer. ... New Zealand Herald Prostate Cancer; Bicalutamide a cost-effective treatment for locally ... - Feb 7, 2005 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- New health economic data outline the cost benefits of the nonsteroidal antiandrogen bicalutamide 150 mg for the ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones … Gynaecomastia and Breast Pain From Bicalutamide: Presented at EAU - Mar 23, 2007 Bicalutamide is the most widely studied nonsteroidal antiandrogen (NSAA) as ... For bicalutamide-induced PSA inhibition, prophylactic tamoxifen had no ... DG News Prostate Cancer; Transcriptional response to bicalutamide treatment … - Mar 28, 2005 ..."Bicalutamide is a non-steroidal anti-androgen commonly used in the ... "Cells treated with 80 microm bicalutamide in steroid-depleted medium for 1 day were ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones … : New Published Data[1] Show That Bicalutamide (Casodex) 150mg Plus... - Feb 1, 2006 New Published Data[1] Show That Bicalutamide (Casodex) 150mg Plus Radiotherapy Significantly Extends Survival in Men With Locally Advanced Prostate Cancer ... Pay-Per-View - PR Newswire Europe - HighBeam Research Counterfiet Casodex recall - Jun 4, 2007 The Medicines and Healthcare products Regulatory Agency (MHRA) has today issued a recall on a counterfeit batch of Casodex Tablets 50 mg (Bicalutamide) with ... Healthcare Republic - Healthcare Republic … And Breast Pain Caused By Bicalutamide Monotherapy: The Role Of … - Dec 12, 2005 BERKELEY, CA (UroToday.com) - While high dose bicalutamide therapy (150 mg/day) has the theoretical advantage of hormonal blockade with less sexual side ... UroToday International Journal Dabur Pharma gets MHRA nod for Bicalutamide tablet - Dec 10, 2008 Dabur Pharma, a specialty pharmaceuticals company with a focus on oncology, has received approval from UK`s Medicines and Healthcare products Regulatory ... Myiris.com Cosudex - Bicalutamide - Medical Drug - Jan 6, 2006 Bicalutamide is used in combination with luteinising hormone releasing hormone (LHRH) agonist therapy in the treatment of advanced prostate cancer. ... Virtual Medical Centre - The Virtual Medical Centre Antineoplastic Bicalutamide Flutamide Nilutamide Description - Oct 27, 2005 Nonsteroidal antiandrogens are used to treat cancer of the prostate gland. The prostate gland is present only in males; therefore, females do not get ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Royal Pharmaceutical Society Advises On Counterfeit Casodex, UK - Jun 8, 2007 The Medicines and Healthcare products Regulatory Agency (MHRA) has today issued a recall on a counterfeit batch of Casodex Tablets 50 mg (Bicalutamide) with ... Medical News Today - Medical News Today (press release) Prostate Cancer; Bicalutamide a cost-effective treatment for locally ... - Feb 11, 2005 2005 FEB 11 - (NewsRx.com & NewsRx.net) -- New health economic data outline the cost benefits of the nonsteroidal antiandrogen bicalutamide 150 mg for the ... Pay-Per-View - Drug Week - Factiva, from Dow Jones … Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA - Sep 22, 2008 AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Prostate Cancer; Transcriptional response to bicalutamide treatment … - Mar 29, 2005 ..."Bicalutamide is a non-steroidal anti-androgen commonly used in the ... "Cells treated with 80 microm bicalutamide in steroid-depleted medium for 1 day were ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Ariad Announces Start of Phase 2 Clinical Study of Oral Deforolimus... - Oct 20, 2008 Patients will be randomized (1:1) to oral deforolimus and bicalutamide vs. placebo and bicalutamide. This is the third Phase 2 clinical trial examining the ... RedOrbit Positive News for Prostate Cancer Patients - Aug 25, 2006 Bicalutamide is a non-steroidal anti-androgen. When tested in 1370 men with early prostate cancer who also underwent radiotherapy, the oral drug showed ... Ivanhoe Broadcast News Prostate Cancer; Transcriptional response to bicalutamide treatment … - Apr 1, 2005 ..."Bicalutamide is a non-steroidal anti-androgen commonly used in the ... "Cells treated with 80 microm bicalutamide in steroid-depleted medium for 1 day were ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Benefits of combined blockade may outweigh risks.(Data show extended ... - Apr 1, 2006 Laurence Klotz, MD, and colleagues demonstrated a benefit of bicalutamide (Casodex) combination therapy versus castration alone when reviewing historical ... $4.95 - Urology Times - ECNext Over-the-counter hormonal dietary supplements may promote prostate … - Jan 16, 2008 Additionally, attempts to stop the cancer-cell growth with increasing concentrations of the anti-cancer drug bicalutamide proved to be futile. ... thecheers.org New Treatment Options For Patients With Prostate Cancer - Nov 3, 2005 Patients received bicalutamide (anti-androgen) or placebo once daily plus ... Additionally bicalutamide produced a trend towards improved OS in patients ... sciencedaily.com New treatment for advanced prostate cancer - Jul 30, 2008 ..."We can now confirm that a very low level of bicalutamide is capable of inhibiting cancer cell proliferation by more than 10-fold when combined with either ... Zee News Drug may be alternative to castration. - Aug 22, 2006 ..."In patients with locally-advanced disease, a daily 150 mg dose of bicalutamide (Casodex) following initial radiotherapy has shown significant clinical ... Free with registration - UPI NewsTrack - AccessMyLibrary.com New treatment options for patients with prostate cancer - Nov 2, 2005 Patients received bicalutamide (anti-androgen) or placebo once daily plus ... Additionally bicalutamide produced a trend towards improved OS in patients ... PsychCentral.com EAU 2007 ABST[25] - The Serum Testosterone Castration Level with … - Mar 21, 2007 Bicalutamide treatment was not related with breakthrough elevations of serum testosterone. However in the subset of patients with breakthrough elevations of ... UroToday International Journal Resveratrol Target SIRT1 Suppresses Cancer - Nov 18, 2007 Bicalutamide suppresses both AR-dependent transcription and prostate cancer cell ... We next assessed whether SIRT1 plays a role in bicalutamide-mediated ... Methuselah Foundation Tamoxifen Can Reduce Breast Pain In Prostate Cancer Patients - Apr 16, 2005 ...(I-Newswire) - A drug called bicalutamide has been licensed in some European ... 51 patients were randomly assigned to 150 mg bicalutamide only per day, ... i-newswire.com AUA 2007 - Prostate Cancer Basic Research (II) - May 21, 2007 To study this the effects of bicalutamide, hydroxyflutamide, nilutamide, ... The researcher concluded that switching bicalutamide to hydroxyflutamide, ... UroToday International Journal ê´‘ë?™ì œì•½, ìœ ë°©ì•”ì¹˜ë£Œì œ 'ë ˆë‚˜ë?¼ì •' 발매 - Oct 22, 2008 ...ê´‘ë?™ì œì•½ 관계ìž?는 “최근 ì „ë¦½ì„ ì•” ì¹˜ë£Œì œì?¸ '비카루드 ì •(Bicalutamide)' ì?„ 출시한 ë?° ì?´ì–´ ì?´ë²ˆì—? ìœ ë°©ì•” ì¹˜ë£Œì œì?¸ 'ë ˆë‚˜ë?¼ ì • (Letrozole)' 까지 출시해 í•ì•”ì œ ... 머니투ë?°ì?´ Prostate Cancer; Recent findings from South Korea, United Kingdom and... - Sep 25, 2006 ..."When the disease relapsed during deferred CAB, bicalutamide was discontinued and ... The researchers concluded, "Deferred CAB therapy using bicalutamide is ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Hacettepe University, Turkey; Study findings from Hacettepe University... - Jan 9, 2007 ..."We prescribed 150 mg/day bicalutamide monotherapy for 24 weeks in patients with ... BC was successfully obtained in 5 of them with only bicalutamide. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Adding antiandrogen to castration improves survival.(20% survival... - May 1, 2005 The trial examined bicalutamide plus a luteinizing hormone-releasing hormone ... In addition, the increased side effects of bicalutamide plus castration ... $4.95 - Urology Times - ECNext [ì¿ í‚¤ë‰´ìŠ¤] ê°“ 구워낸 ë°”ì‚ë°”ì‚í•œ 뉴스 - Sep 4, 2008 ...[ì¿ í‚¤ ê±´ê°•] ê´‘ë?™ì œì•½ì?´ 비칼루타마ì?´ë“œ(Bicalutamide) 성분ì?˜ ì „ë¦½ì„ ì•” ì¹˜ë£Œì œì?¸ ' 비카루드 ì •'ì?„ 출시했다. ê´‘ë?™ì œì•½ì—? 따르면 '비카루드 ì •'ì?€ 안드로ê²?(Androgen) ... ì¿ í‚¤ë‰´ìŠ¤ Il blocco androgenico combinato prolunga l'ormonosensibilità - Jun 12, 2007 Bicalutamide è un antiandrogeno non-steroideo che si lega direttamente ai recettori cellulari per il testosterone, potenziando così il blocco della crescita ... yahoo.net Actavis launches generic drug for prostate cancer - Jul 22, 2008 Bicalutamide from Acatvis pharmaceuticals is the first generic version of the prostate ... Bicalutamide, the generic version of AstraZeneca's Casodex, ... webwire.com Drug Combo Effective for Prostate Cancer Cytoreduction Before … - Aug 15, 2006 Bicalutamide and dutasteride are antiandrogen agents, which in combination may offer ... Bicalutamide works by binding androgen receptors in target tissues, ... Cancerpage.com Bicalutamide: arma efficace contro il tumore della prostata - Nov 4, 2005 La notizia. Chiarire il ruolo della terapia antiandrogenica in pazienti con tumore della prostata è stato l'obiettivo dell'Early Prostate Cancer programme ... yahoo.net State Of The Art Lecture: Molecular Biology Of Prostate Cancer And... - May 24, 2006 Bicalutamide becomes a weak agonist in this setting. Bicalutamide then induces androgen-regulated genes and may help to explain the anti-androgen withdrawal ... Medical News Today - Medical News Today (press release) Casodex® 150 mg (bicalutamide) wordt in België van de markt … - Aug 19, 2005 Casodex®, op basis van het anti-androgeen bicalutamide, is beschikbaar als comprimés aan 50 mg en aan 150 mg voor gebruik bij prostaatcarcinoom. ... Belgisch centrum voor farmacotherapeutis... Does small-cell phenotype predict the natural history of prostate... - Jan 20, 2007 Oral bicalutamide was started at 50 mg daily for 6 weeks, providing transient but symptomatic relief. MRI of the abdomen and pelvis performed 2 months after ... Nature.com Prostate Cancer: New choice for hormone refractory patients. - Dec 8, 2005 London - While the use of AstraZeneca's bicalutamide monotherapy in prostate cancer continues, its use has significantly decreased in localized stage ... $4.95 - M2 Presswire - ECNext AUA 2006 - Society of Urologic Oncology Meeting: State of the Art... - May 19, 2006 Bicalutamide becomes a weak agonist in this setting. Bicalutamide then induces androgen-regulated genes and may help to explain the anti-androgen withdrawal ... UroToday International Journal Definitive radiotherapy with adjuvant long-term antiandrogen treatment... - Nov 20, 2008 Bicalutamide 150 mg 1 replaced flutamide in cases of intolerance. ... This question has been actualized as bicalutamide monotherapy compared with placebo ... Nature.com Case study: management of lymph node-positive disease detected at … - May 20, 2005 Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the ... Nature.com New treatment options for patients with prostate cancer - Mar 11, 2005 Patients received bicalutamide (anti-androgen) or placebo once daily plus ... Additionally bicalutamide produced a trend towards improved OS in patients ... innovations report The Early Prostate Cancer Trial And Adjuvant Anti-androgen Therapy: … - Feb 25, 2006 It evaluated adjuvant bicalutamide in patients across the world that still had their ... For example, bicalutamide plus standard care improved objective ... Medical News Today - Medical News Today (press release) Management of locally advanced prostate cancer - Dec 1, 2008 The antiandrogens (eg, 150 mg bicalutamide) are given orally and may have ... Bicalutamide 150 mg helped maintain physical capacity and bone mineral density ... Nature.com Alternative Nonsteroidal Antiandrogen Therapy For Advanced Prostate … - Aug 17, 2008 Of the 193 men initially treated with bicalutamide, 143 (74%) achieved a complete ... Antiandrogen withdrawal response rates were 15.5% for bicalutamide and ... Medical News Today - Medical News Today (press release) Limited Utility of Bone Scans for Men with Recurrent Prostate Cancer... - Jul 24, 2006 The figures were similar for men in the placebo and bicalutamide arms. For men who had radical prostatectomy as primary therapy, the incidence of positive ... UroToday International Journal Limited Utility Of Bone Scans For Men With Recurrent Prostate Cancer ... - Aug 2, 2006 The figures were similar for men in the placebo and bicalutamide arms. For men who had radical prostatectomy as primary therapy, the incidence of positive ... Medical News Today - Medical News Today (press release) Potentially Harmful Effect of a Testosterone Dietary Supplement on … - Jan 28, 2008 Blocking experiments with serial increases of the potent nonsteroidal competitive antagonist of androgen receptor bicalutamide revealed that the product ... Archives of Internal Medicine Antiandrogens, Nonsteroidal (Systemic).(drug overview)(Drug overview) - Aug 1, 2006 Bicalutamide and nilutamide may be taken with food or on an empty stomach. ... Children -- It is unlikely that bicalutamide would be needed to treat cancer ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com BMS 641988 Bristol-Myers Squibb preclinical data. - May 8, 2006 641988 or bicalutamide showed that there were a significantly larger number of peptides displaying positive dose dependence with BMS 641988 than with ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones MyFox Lubbock | Casodex - Uses, Side Effects, Interactions, Warnings,... - Mar 2, 2007 Bicalutamide belongs to a group of medications known as nonsteroidal antiandrogens. Nonsteroidal antiandrogens such as bicalutamide block the effect of the ... myFOXlubbock.com New Data For Prolonging Hormonal Response In Locally Advanced And … - Mar 23, 2007 After disease progression, all 122 patients received CAB 'step-up' treatment, by the addition of bicalutamide 50mg (CASODEX) to their existing goserelin ... Medical News Today - Medical News Today (press release) Redefining Clinically Significant Castration Levels In Patients With ... - Sep 24, 2007 Bicalutamide was continued as combination therapy in 28 men. ... Patients on bicalutamide as maximal androgen blockade had similar testosterone ... Medical News Today - Medical News Today (press release) Men with prostate cancer worse off than women with breast cancer - Jul 31, 2005 Bicalutamide 150mg is a non-steroidal anti-androgen, indicated for locally advanced ... Bicalutamide 150mg monotherapy offers an alternative treatment, ... Medical News Today - Medical News Today (press release) Are Bone Scans Necessary in Men with Low Prostate Specific Antigen … - Oct 10, 2006 Analysis of results showed that the incidence of positive bone scans in patients treated with watchful waiting and given bicalutamide or placebo was low ... UroToday International Journal Are Bone Scans Necessary In Men With Low Prostate Specific Antigen … - Oct 16, 2006 Analysis of results showed that the incidence of positive bone scans in patients treated with watchful waiting and given bicalutamide or placebo was low ... Medical News Today - Medical News Today (press release) Prostate Cancer - A Prostrate Market Waiting For Innovations. - Nov 21, 2005 Safety concerns with AstraZenecas Casodex (bicalutamide) have also seen a ... The use of bicalutamide has significantly decreased in localized stage between ... Free with registration - M2 Presswire - AccessMyLibrary.com Press Release: Prostate Cancer - A Prostrate Market Waiting For … - Nov 21, 2005 Safety concerns with AstraZenecas Casodex (bicalutamide) have also seen a ... The use of bicalutamide has significantly decreased in localized stage between ... Pay-Per-View - M2 Presswire - HighBeam Research Androgen deficit linked to QT prolongation in men.(Men's Health)(Brief... - Mar 15, 2005 In the first study, 177 men were treated with abarelix or with goserelin plus bicalutamide. In the second study, abarelix was compared with leuprolide, ... Pay-Per-View - Family Practice News - HighBeam Research Inappropriate treatment of prostate cancer caused by heterophilic … - Jan 18, 2008 Management The patient was started on androgen deprivation therapy with goserelin acetate and bicalutamide. At 3 months, he was asymptomatic, his prostate ... Nature.com A case of prostatic adenocarcinoma recurrence presenting as ductal … - May 27, 2007 Approximately 6 months before the current presentation, bicalutamide 50 mg was added to his treatment because of PSA recurrence (PSA level increased to 2.8 ... Nature.com Tumore della prostata: confermata l'importanza dell'ormonoterapia - Nov 15, 2005 ...“A questo riguardoâ€?, ribadisce il dottor Conti, “bicalutamide 150 mg esce senza dubbio ... Con bicalutamide 150 mg l'effetto collaterale maggiore è la ... yahoo.net Hormonal Treatment For Localized And Advanced Prostate Cancer - Apr 2, 2007 Twenty-eight of these men were also on bicalutamide. ... Bicalutamide was not stated to be related with breakthrough elevations of testosterone, ... Medical News Today - Medical News Today (press release) Prostate Cancer in a Transgender Woman 41 Years After Initiation of … - Nov 15, 2006 Antiandrogen treatment with oral bicalutamide (50 mg daily) and oral dutasteride (0.5 mg ... Bicalutamide (an antiandrogen) was used to block AR signaling, ... Journal of American Medical Association - Journal of American Medical Association... Warning over fake batch of 'lifesaving' cancer medicine - Feb 6, 2007 It contains the active ingredient bicalutamide and works by blocking the action of the male hormone testosterone in fuelling prostate cancer. ... This is London EAU 2007 - Hormonal Treatment for Localized and Advanced Prostate … - Mar 29, 2007 Twenty-eight of these men were also on bicalutamide. ... Bicalutamide was not stated to be related with breakthrough elevations of testosterone, ... UroToday International Journal Bone Scans Not Needed in Men with Low PSA After Localized Prostate … - Jul 27, 2006 For men treated with watchful waiting and the anti-androgen bicalutamide or placebo, the incidence of positive bone scans in was low (0.7% to 3.2%) when the ... Cancerpage.com Hormonal Dietary Supplements Might Promote Prostate Cancer … - Jan 11, 2008 Additionally, attempts to stop the cancer-cell growth with increasing concentrations of the anti-cancer drug bicalutamide proved to be futile. ... newswise.com Testosterone Suppression Speedily Reversed - Mar 23, 2005 In six of the seven hormonal therapy-naive patients, there was a significant increase in testosterone and LH within 7 days of starting bicalutamide. ... Cancerpage.com GU Cancers Symposium - ASCO ASTRO SUO - 2008 - High-Risk … - Feb 16, 2008 In the EPC trial, 1719 men with high risk disease had a survival advantage with 150mg bicalutamide. This supports the use of systemic therapy, (but doesn't ... UroToday International Journal Researchers Develop New Treatment For Prostate Cancer - Aug 1, 2008 Dr Lisa Butler said, “We can now confirm that a very low level of bicalutamide is capable of inhibiting cancer cell proliferation by more than 10-fold when ... TopNews Interleukin-4 Stimulates Androgen-Independent Growth in LNCaP Human … - Jan 2, 2008 The DHT-mediated cell growth could not be blocked by bicalutamide in IL-4 overexpressing LNCaP cells, but can be neutralized by bicalutamide in parental ... UroToday International Journal EAU 2007 - Step-Up to CAB May Prolong PSA Response in Patients with … - Mar 29, 2007 Importantly, addition of bicalutamide 50 mg was associated with very little additional morbidity in patients already receiving goserelin. ... UroToday International Journal Early therapy is not helpful for recurrent prostate cancer.(Men's... - May 1, 2007 It also stated that a newer nonsteroidal antiandrogen agent, bicalutamide, is preferable to older agents such as flutamide. "New data suggest bicalutamide ... Free with registration - Family Practice News - AccessMyLibrary.com URS 2007 - Androgen Receptor Coactivator ART-27 Regulates Cell … - Oct 27, 2007 In addition, our preliminary data suggests genes repressed by administration of bicalutamide, an AR antagonist, are no longer repressed in the absence of ... UroToday International Journal AUA 2007 - Systemic Therapy of Advanced Prostate Cancer II - May 24, 2007 Bone mineral increase was improved by DEXA scan in all patients and in the bicalutamide patients in particular. 16% of patients had lumbar compression ... UroToday International Journal Treatment options for prostate adenocarcinoma - Nov 10, 2008 Bicalutamide (Casodex, AstraZeneca) was added and he was referred for local ... His performance status remained reasonably good, so bicalutamide was ... HemOncToday FED: Less drug, more benefits for prostate cancer | Article from AAP ... - Jul 29, 2008 ..."We can now confirm that a very low level of bicalutamide is capable of inhibiting cancer cell proliferation by more than ten-fold when combined with either ... Pay-Per-View - AAP General News - HighBeam Research Brand Names/Synonyms: Bicalutamide is also known by the following brand names and/or synonymsBicalutamide; Bicalutamide [Usan:Ban:Inn]; Casodex Drug Category: Bicalutamide is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BB03 Dosage Forms: TABLET Absorption: Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |